.
Paradoxically, the disease that may follow its outgrowth necessitates further antimicrobial treatment. Already a major challenge to infection prevention and control strategies, there are indications that C. difficile is developing further resistance to currently used antimicrobial agents. The emergence and rapid transmission of C. difficile strains resistant to multiple antimicrobials is now a significant problem worldwide. C. difficile has evolved multiple mechanisms for antimicrobial resistance (AMR) including chromosomal mutations and acquired mobile genetic elements (MGE), causing alterations in the targets of antimicrobials and/or in metabolic pathways. Rates of AMR in C. difficile vary considerably between studies, related to geography and antimicrobial policy. In this short review, important classes of antimicrobial agents will be discussed in relation to their role in inducing and treating CDI.
Antimicrobials that incite CDI b-Lactams
Broad spectrum b-lactam antimicrobials such as aminopenicillins and cephalosporins are known for their propensity to cause CDI 3 .
Cephalosporin resistance is a hallmark of C. difficile; data extrapolated from previous studies revealed that the majority of C. difficile isolates tested were resistant (95% second generation; 38% third generation) and there is usually significant clustering around the breakpoint 6 . Thus, C. difficile is often described as 'intrinsically resistant' to cephalosporins, mediated by class D b-lactamases and a b-lactam inducing penicillin binding protein encoded on cdd and blaR genes, respectively 7, 8 .
Macrolide-lincosamide-streptogramin B (MLS B )
The macrolide-lincosamide-streptogramin (MLS) B class of antimicrobials contains structurally different but functionally similar drugs, that all bind to the 50S ribosomal subunit 9 . Clindamycin was the first antimicrobial agent linked to PMC in the mid-1970s 2 .
Although the use of clindamycin has declined since its close association with CDI was first described, clindamycin resistance remains common 10 . Erythromycin is a macrolide that inhibits protein synthesis. Macrolides alone do not have a strong association with CDI; however, the true risks are likely underestimated given that macrolides are often co-administered with other antimicrobial agents 13 . Similar to clindamycin, erythromycin resistance may be mediated through the expression of ermB, as well as ermFS, mutation in 23S rDNA and a possible cme efflux pump 11, 14, 15 . 
Vancomycin
Vancomycin is the first-line treatment for moderate to severe CDI 
Rifamycins
The rifamycins achieve selective toxicity in bacteria by targeting bacterial DNA-dependent RNA polymerase 27 . Both rifampicin and rifaximin have been used to treat CDI due to very low MICs and they are often used as adjunctive post-vancomycin therapy for recurrent CDI 17 .
One potential concern about the use of rifaximin is the rapid development of resistance during treatment 27 . Resistance is likely conferred by RpoB amino acid substitutions that appear to be independently derived rather than disseminated from specific resistant clones 27 . Thus, prolonged use of rifamycins is not recommended.
Fidaxomicin
Fidaxomicin is a macrocyclic narrow spectrum bactericidal agent that targets bacterial RNA polymerase 28 . It is the first drug to be licensed and recommended for CDI treatment for adults in over 
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